These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8192105)

  • 21. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
    Link KH; Sunelaitis E; Kornmann M; Schatz M; Gansauge F; Leder G; Formentini A; Staib L; Pillasch J; Beger HG
    Cancer; 2001 Dec; 92(11):2746-53. PubMed ID: 11753947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study.
    Maisano R; Caristi N; Mare M; Raffaele M; Iorfida M; Mafodda A; Zavettieri M; Nardi M
    Anticancer Res; 2007; 27(4C):2871-5. PubMed ID: 17695463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study.
    Kalofonos HP; Onyenadum A; Kosmas C; Koutras A; Petsas T; Efthimiou V; Koukouras D; Tzoracolefterakis E; Andrikopoulos P; Androulakis J
    Tumori; 2001; 87(6):394-7. PubMed ID: 11989593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
    Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM
    Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
    Sato K; Hiraide H; Tamakuma S; Tabei T; Maruyama M; Touma M; Okamura H; Matsumoto F; Akao S; Ishikawa H; Yagi Y; Mochizuki H
    Breast Cancer; 2001; 8(1):58-62. PubMed ID: 11180767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.
    Belpomme D; Heritier F; Gisselbrecht C; Marty M; Michaud G; Le Rol A; Cour V; George C; Maral J
    Cancer Treat Rep; 1987 Sep; 71(9):845-7. PubMed ID: 3621218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
    Massacesi C; La Cesa A; Marcucci F; Pilone A; Rocchi MB; Zepponi L; Santini D; Tonini G; Burattini L
    Oncology; 2006; 70(4):294-300. PubMed ID: 17047400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
    Panagos GE
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S17-21. PubMed ID: 9071335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
    Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
    J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer.
    Vici P; Di Lauro L; Carpano S; Amodio A; Pignatti F; Casali A; Conti F; Lopez M
    Oncology; 1996; 53(1):16-8. PubMed ID: 8570125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.
    Iino Y; Yokoe T; Sugamata N; Maemura M; Takei H; Horiguchi J; Takeyoshi I; Ohwada S; Morishita Y; Kusaba T; Ishida T; Yokomori T; Fujii T; Endo K; Shiozaki H; Aiba S; Takano A; Kishi S
    Cancer Chemother Pharmacol; 1998; 41(3):243-7. PubMed ID: 9443642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of current chemotherapy in metastatic breast cancer resistant to anthracycline antibiotics].
    Moiseenko VM; Orlova RV
    Vopr Onkol; 1999; 45(4):445-8. PubMed ID: 10532109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
    Mavroudis D; Alexopoulos A; Malamos N; Ardavanis A; Kandylis C; Stavrinidis E; Kouroussis Ch; Agelaki S; Androulakis N; Bozionelou V; Georgoulias V
    Oncology; 2003; 64(3):207-12. PubMed ID: 12697959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancer.
    Yokoe T; Iino Y; Sugamata N; Aoyagi H; Takai Y; Takei H; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1995; 15(5B):2303-5. PubMed ID: 8572643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer.
    Kariya S; Ogawa Y; Nishioka A; Yoshida S
    Oncol Rep; 2002; 9(6):1345-9. PubMed ID: 12375046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.